---
name: An AAV Platform Advancing Successful Viral Vector Based Therapeutics - FUJIFILM Biotechnologies
slug: fujifilmbiotechnologies
site: cro
website_domain: fujifilmbiotechnologies.fujifilm.com
summary: An AAV Platform Advancing Successful Viral Vector Based Therapeutics - FUJIFILM Biotechnologies provides CRO services. Discovery_source:brave. Headquartered in Hillerød, Denmark.
tagline: CDMO partner combining technical leadership in cell culture, fermentation, and cell & gene therapy with world-class cGMP manufacturing.
founded_year: 
employee_count_band: 
employee_count_label: 
parent_name: 
parent_slug: 
hq_country: DK
tier2_domain_verified: false
updated_at: 2026-06-10T01:45:19.034Z
services_count: 3
modalities_count: 4
indications_count: 0
locations_count: 2
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# An AAV Platform Advancing Successful Viral Vector Based Therapeutics - FUJIFILM Biotechnologies

CDMO partner combining technical leadership in cell culture, fermentation, and cell & gene therapy with world-class cGMP manufacturing.

Listed on cro.directory.

## Summary

An AAV Platform Advancing Successful Viral Vector Based Therapeutics - FUJIFILM Biotechnologies provides CRO services. Discovery_source:brave. Headquartered in Hillerød, Denmark.

## At a glance

- HQ country: DK

## Services

- Medical Writing
- Regulatory Affairs
- Translational Research

## Modalities

- Biologics (Other)
- Vaccine
- Cell Therapy
- Gene Therapy

## Locations

- US Facility, United States
- Hillerød, Hillerød, Denmark

## Long description

FUJIFILM Biotechnologies is a CDMO partner specializing in biologics, advanced therapies, and vaccines. The organization provides end-to-end support across the development lifecycle:

**Development & Manufacturing Services:**
- Pre-clinical: cell line and strain development, manufacturability assessments, cell banking, and toxicology material generation to support IND/IMPD submission
- Clinical Phase I & II: development of initial clinical cGMP drug substance and drug product manufacturing processes
- Clinical Phase III: process optimization, scaling, and characterization to meet therapeutic demands
- Commercialization: process validation, process performance qualification, CMC and regulatory services for BLA/MAA submission

**Technical Capabilities:**
The company combines technical leadership in cell culture, microbial fermentation, and cell and gene therapy with world-class cGMP manufacturing facilities. Operations leverage the KojoX operational ecosystem—a modular approach featuring process modules for customer-specific recipes, equipment modules for flexible standardized configurations, and procedural modules ensuring high-quality cGxP execution.

**Facilities & Infrastructure:**
Production facilities located in the US and Europe support development and commercialization of treatments and therapies. Recent expansion includes a new laboratory doubling quality control footprint at the Hillerød commercial-scale manufacturing site.

**Recognition:**
Named a 2026 CDMO Leadership Award Winner, reflecting verified sponsor feedback and excellence in outsourcing performance for biologics innovation.

_Profile last updated: 2026-06-10T01:45:19.034Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.